Crescent Biopharma (NASDAQ:CBIO) Stock Rating Reaffirmed as Buy by HC WainwrightDefense World · 5 days ago
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001GlobeNewsWire · Oct 15, 2026
Crescent Biopharma Announces Grants of Inducement AwardsGlobeNewsWire · Oct 6, 2026
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid TumorsGlobeNewsWire · Oct 5, 2026
Crescent Biopharma Announces Grants of Inducement AwardsGlobeNewsWire · Sep 25, 2026
Insider Selling: Crescent Biopharma (NASDAQ:CBIO) Insider Sells $11,098.00 in StockDefense World · Sep 21, 2026Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | -$0.74 | -$0.74 | Miss |
| Apr 29, 2026 | -$0.85 | -$0.70 | Beat |
| Feb 26, 2026 | -$2.22 | -$4.01 | Miss |
| Nov 6, 2025 | -$1.01 | -$1.27 | Miss |
| Aug 6, 2025 | -$2.69 | -$4.93 | Miss |
| May 14, 2025 | -$5.00 | -$0.04 | Beat |